Fung, famotidine prophylaxis study: no change in mortality [p=1], 6% lower hospitalization [p=0.0002], and 12% more cases [p<0.0001] https://c19p.org/fungfm
copied to clipboard
Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients
et al., PLoS ONE, doi:10.1371/journal.pone.0266922 (preprint 10/1/2021)
Retrospective database analysis of 374,229 patients in the USA, showing higher cases, lower hospitalizations, and no change in mortality with famotidine use.
|
risk of death, no change, HR 1.00, p = 1.00, vs. never used.
|
|
risk of hospitalization, 6.0% lower, HR 0.94, p < 0.001, vs. never used.
|
|
risk of case, 12.0% higher, HR 1.12, p < 0.001, vs. never used.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
not fully adjusting for the different baseline risk of systemic autoimmune patients.
Fung et al., 10/1/2021, retrospective, population-based cohort, USA, North America, peer-reviewed, 6 authors.
fung
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.